glp-1 and afib Drugs Show Growing Promise for Control New research presented at #HRS2026

9 The current advantages, research stage and areas of opportunity of small molecule GLP-1RAs is summarized in Figure 3

It is important to note that naltrexone/bupropion may have safety concerns, such as the risk of depression, hypertension, seizures, acute opioid withdrawal, and opioid overuse

The user base is already large enough that it shapes check averages, category mix, and menu performance in measurable ways

Yes, through the patient-specific pathway: your prescriber documents your individual need and a licensed pharmacy prepares the personalized dose

Clinical Oversight & Safety Licensed providers (may include video consultations, not just asynchronous) Partner compounding pharmacies comply with USP 795 and USP 797 safety standards The 2-month minimum commitment is non-negotiable